Updated Jun. 18, 2012 at 5:30 a.m.
GSK
"The company continues to believe that this offer reflects full and fair value and is in the interest of shareholders of both companies," GSK said in a statement....
GSK's $2.6B hostile takeover bid for Human Genome is still on
Post a comment
Print this blog postE-mail blog post
Share
GSK
"The company continues to believe that this offer reflects full and fair value and is in the interest of shareholders of both companies," GSK said in a statement....
WRAL Tech Wire any time: Twitter, Facebook
Copyright 2013 WRAL Tech Wire. All rights reserved.Please log in to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
Please Log In to add a comment.
Best of TechWire Insider
OUR INSIDERS
WRAL TechWire Editor
The Skinny
NC Biotech Center braces for worst as Senate slashes budget, too- ArchiveSocial, a new Durham success story, brings home international award
- Durham's high-tech infrastructure, talent lure Virginia company
- Lenovo acknowledges layoffs in Morrisville as part of shift to 'PC Plus' strategy
- Raleigh-based PRA International eyes public offering
- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows